Review



upa inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress upa inhibitor
    Upa Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/upa inhibitor/product/MedChemExpress
    Average 93 stars, based on 2 article reviews
    upa inhibitor - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    upa inhibitor  (MedChemExpress)
    93
    MedChemExpress upa inhibitor
    Upa Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/upa inhibitor/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    upa inhibitor - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    human pai  (Innovative Research Inc)
    92
    Innovative Research Inc human pai
    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type <t>1</t> <t>(PAI-1)</t> (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. <t>The</t> <t>PAI-1</t> in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.
    Human Pai, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pai/product/Innovative Research Inc
    Average 92 stars, based on 1 article reviews
    human pai - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    jak inhibitors tof, bar, pef, upa, fil  (Cayman Chemical)
    90
    Cayman Chemical jak inhibitors tof, bar, pef, upa, fil
    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type <t>1</t> <t>(PAI-1)</t> (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. <t>The</t> <t>PAI-1</t> in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.
    Jak Inhibitors Tof, Bar, Pef, Upa, Fil, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jak inhibitors tof, bar, pef, upa, fil/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    jak inhibitors tof, bar, pef, upa, fil - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    serine protease upa inhibitor uamc-00050  (Technik GmbH)
    90
    Technik GmbH serine protease upa inhibitor uamc-00050
    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type <t>1</t> <t>(PAI-1)</t> (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. <t>The</t> <t>PAI-1</t> in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.
    Serine Protease Upa Inhibitor Uamc 00050, supplied by Technik GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/serine protease upa inhibitor uamc-00050/product/Technik GmbH
    Average 90 stars, based on 1 article reviews
    serine protease upa inhibitor uamc-00050 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    upa selective inhibitor uk122  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology upa selective inhibitor uk122
    Figure 5. Effect of uPA inhibitor on DSS-induced colitis in C57BL/6 J mice. (A) Male mice were administered 2% DSS in their drinking water for 1 week, and intraperitoneally injected with 2 mg/kg or 4 mg/kg <t>UK122</t> or vehicle from day 1 to day 7 (n = 18 per group). They were sacrificed at day 8. (B) Representative macroscopic images of the colon in each group. The lower right panel represents a colorectum of mice that did not receive DSS. (C) DAI was evaluated at day 8 by the scoring method of Cooper et al.10 (D) Representative H&E staining images of colon sections in each group. The lower right panel represents a colorectum of mice that did not receive DSS. Scale bar, 100 μm. (E) Histologic score of H&E staining image was evaluated by the scoring method of Williams et al.11 Data represent mean ± SEM. *p < 0.05, **p < 0.01 by Dunnett’s multiple comparison test.
    Upa Selective Inhibitor Uk122, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/upa selective inhibitor uk122/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    upa selective inhibitor uk122 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    upa stop-upa inhibitor  (American Diagnostica)
    90
    American Diagnostica upa stop-upa inhibitor
    Inhibition of <t>uPA</t> activity does not <t>prevent</t> <t>LPA-induced</t> E-cadherin junction disruption. OVCA429 cells were treated with or without LPA (30 μ M), as indicated, for 18 hours in the presence or absence of the uPA inhibitor designated uPA Stop (2.5 μ M), as indicated and processed for immunofluorescence staining for E-cadherin using anti-E-cadherin ectodomain antibody (1 : 300) and Alexa Fluor 488-conjugated secondary antibody (1 : 500; green). Blue-DAPI-stained nuclei.
    Upa Stop Upa Inhibitor, supplied by American Diagnostica, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/upa stop-upa inhibitor/product/American Diagnostica
    Average 90 stars, based on 1 article reviews
    upa stop-upa inhibitor - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human urokinase type plasminogen activator upa  (Innovative Research Inc)
    92
    Innovative Research Inc human urokinase type plasminogen activator upa
    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active <t>enzyme),</t> <t>urokinase-type</t> plasminogen activator <t>(uPA),</t> and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type 1 (PAI-1) (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. The PAI-1 in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.
    Human Urokinase Type Plasminogen Activator Upa, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human urokinase type plasminogen activator upa/product/Innovative Research Inc
    Average 92 stars, based on 1 article reviews
    human urokinase type plasminogen activator upa - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type 1 (PAI-1) (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. The PAI-1 in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type 1 (PAI-1) (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. The PAI-1 in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Blocking Assay

    Measurements for the plasmin system in human milk from all lactating women in the study.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: Measurements for the plasmin system in human milk from all lactating women in the study.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postnatal age at sampling. (A) Plasmin activity across postnatal age; (B) human urokinase-type plasminogen activator (uPA) across postnatal age; (C) human tissue-type plasminogen activator (tPA) across postnatal age; (D) human plasminogen activator inhibitor type 1 (PAI-1) across postnatal age in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postnatal age at sampling. (A) Plasmin activity across postnatal age; (B) human urokinase-type plasminogen activator (uPA) across postnatal age; (C) human tissue-type plasminogen activator (tPA) across postnatal age; (D) human plasminogen activator inhibitor type 1 (PAI-1) across postnatal age in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Sampling, Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across gestational age (GA) at birth. (A) Plasmin activity across GA; (B) human urokinase-type plasminogen activator (uPA) across GA; (C) human tissue-type plasminogen activator (tPA) across GA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across GA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across gestational age (GA) at birth. (A) Plasmin activity across GA; (B) human urokinase-type plasminogen activator (uPA) across GA; (C) human tissue-type plasminogen activator (tPA) across GA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across GA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postmenstrual age (PMA). (A) Plasmin activity across PMA; (B) human urokinase-type plasminogen activator (uPA) across PMA; (C) human tissue-type plasminogen activator (tPA) across PMA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across PMA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postmenstrual age (PMA). (A) Plasmin activity across PMA; (B) human urokinase-type plasminogen activator (uPA) across PMA; (C) human tissue-type plasminogen activator (tPA) across PMA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across PMA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay

    Figure 5. Effect of uPA inhibitor on DSS-induced colitis in C57BL/6 J mice. (A) Male mice were administered 2% DSS in their drinking water for 1 week, and intraperitoneally injected with 2 mg/kg or 4 mg/kg UK122 or vehicle from day 1 to day 7 (n = 18 per group). They were sacrificed at day 8. (B) Representative macroscopic images of the colon in each group. The lower right panel represents a colorectum of mice that did not receive DSS. (C) DAI was evaluated at day 8 by the scoring method of Cooper et al.10 (D) Representative H&E staining images of colon sections in each group. The lower right panel represents a colorectum of mice that did not receive DSS. Scale bar, 100 μm. (E) Histologic score of H&E staining image was evaluated by the scoring method of Williams et al.11 Data represent mean ± SEM. *p < 0.05, **p < 0.01 by Dunnett’s multiple comparison test.

    Journal: Scientific reports

    Article Title: Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.

    doi: 10.1038/s41598-023-29824-1

    Figure Lengend Snippet: Figure 5. Effect of uPA inhibitor on DSS-induced colitis in C57BL/6 J mice. (A) Male mice were administered 2% DSS in their drinking water for 1 week, and intraperitoneally injected with 2 mg/kg or 4 mg/kg UK122 or vehicle from day 1 to day 7 (n = 18 per group). They were sacrificed at day 8. (B) Representative macroscopic images of the colon in each group. The lower right panel represents a colorectum of mice that did not receive DSS. (C) DAI was evaluated at day 8 by the scoring method of Cooper et al.10 (D) Representative H&E staining images of colon sections in each group. The lower right panel represents a colorectum of mice that did not receive DSS. Scale bar, 100 μm. (E) Histologic score of H&E staining image was evaluated by the scoring method of Williams et al.11 Data represent mean ± SEM. *p < 0.05, **p < 0.01 by Dunnett’s multiple comparison test.

    Article Snippet: The uPA-selective inhibitor UK122 (Santa Cruz Biotechnology, Dallas, TX) was dissolved in dimethyl sulfoxide (DMSO) and saline.

    Techniques: Injection, Staining, Comparison

    Figure 6. Cytokine expression in colorectal tissue from DSS-treated uPA−/− mice, and C57BL/6 J mice intraperitoneally injected with UK122. (A) Cytokine concentration in the colorectal extracts of WT (n = 8) and uPA−/− (n = 10) mice measured using Bio-Plex Pro Mouse Cytokine 23-Plex Assay kit in triplicate. (B) Cytokine concentration in the colorectal extracts of 8 mice treated with 2 mg/kg or 4 mg/kg UK122 or vehicle measured using Bio-Plex Pro Mouse Cytokine 23-Plex Assay kit in duplicate. Data represent mean ± SEM. *p < 0.05, by Student’s t test (A) and Dunnett’s multiple comparison test (B).

    Journal: Scientific reports

    Article Title: Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.

    doi: 10.1038/s41598-023-29824-1

    Figure Lengend Snippet: Figure 6. Cytokine expression in colorectal tissue from DSS-treated uPA−/− mice, and C57BL/6 J mice intraperitoneally injected with UK122. (A) Cytokine concentration in the colorectal extracts of WT (n = 8) and uPA−/− (n = 10) mice measured using Bio-Plex Pro Mouse Cytokine 23-Plex Assay kit in triplicate. (B) Cytokine concentration in the colorectal extracts of 8 mice treated with 2 mg/kg or 4 mg/kg UK122 or vehicle measured using Bio-Plex Pro Mouse Cytokine 23-Plex Assay kit in duplicate. Data represent mean ± SEM. *p < 0.05, by Student’s t test (A) and Dunnett’s multiple comparison test (B).

    Article Snippet: The uPA-selective inhibitor UK122 (Santa Cruz Biotechnology, Dallas, TX) was dissolved in dimethyl sulfoxide (DMSO) and saline.

    Techniques: Expressing, Injection, Concentration Assay, Plex Assay, Comparison

    Inhibition of uPA activity does not prevent LPA-induced E-cadherin junction disruption. OVCA429 cells were treated with or without LPA (30 μ M), as indicated, for 18 hours in the presence or absence of the uPA inhibitor designated uPA Stop (2.5 μ M), as indicated and processed for immunofluorescence staining for E-cadherin using anti-E-cadherin ectodomain antibody (1 : 300) and Alexa Fluor 488-conjugated secondary antibody (1 : 500; green). Blue-DAPI-stained nuclei.

    Journal: Journal of Oncology

    Article Title: Lysophosphatidic Acid Disrupts Junctional Integrity and Epithelial Cohesion in Ovarian Cancer Cells

    doi: 10.1155/2012/501492

    Figure Lengend Snippet: Inhibition of uPA activity does not prevent LPA-induced E-cadherin junction disruption. OVCA429 cells were treated with or without LPA (30 μ M), as indicated, for 18 hours in the presence or absence of the uPA inhibitor designated uPA Stop (2.5 μ M), as indicated and processed for immunofluorescence staining for E-cadherin using anti-E-cadherin ectodomain antibody (1 : 300) and Alexa Fluor 488-conjugated secondary antibody (1 : 500; green). Blue-DAPI-stained nuclei.

    Article Snippet: In some experiments, cells were pretreated prior to addition of LPA with inhibitor (or equivalent concentrations of DMSO) for 1.5 to 3 hours (GM6001-MMP inhibitor, Chemicon, 25 μ M; Ki16425-LPA receptor inhibitor, Cayman Chemical, 40 μ M; uPA Stop-uPA inhibitor, American Diagnostica, 2.5 μ M).

    Techniques: Inhibition, Activity Assay, Immunofluorescence, Staining

    Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type 1 (PAI-1) (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. The PAI-1 in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: Human milk’s plasmin system is composed of plasminogen (zymogen), plasmin (the active enzyme), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (plasminogen activators), and human plasminogen activator inhibitor type 1 (PAI-1) (plasminogen activator inhibitor). Plasminogen (the inactive zymogen) must be cleaved by uPA or tPA to become the active plasmin. The PAI-1 in human milk can block the activators’ (both tPA and uPA) conversion of plasminogen to active plasmin.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Blocking Assay

    Measurements for the plasmin system in human milk from all lactating women in the study.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: Measurements for the plasmin system in human milk from all lactating women in the study.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postnatal age at sampling. (A) Plasmin activity across postnatal age; (B) human urokinase-type plasminogen activator (uPA) across postnatal age; (C) human tissue-type plasminogen activator (tPA) across postnatal age; (D) human plasminogen activator inhibitor type 1 (PAI-1) across postnatal age in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postnatal age at sampling. (A) Plasmin activity across postnatal age; (B) human urokinase-type plasminogen activator (uPA) across postnatal age; (C) human tissue-type plasminogen activator (tPA) across postnatal age; (D) human plasminogen activator inhibitor type 1 (PAI-1) across postnatal age in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Sampling, Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across gestational age (GA) at birth. (A) Plasmin activity across GA; (B) human urokinase-type plasminogen activator (uPA) across GA; (C) human tissue-type plasminogen activator (tPA) across GA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across GA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across gestational age (GA) at birth. (A) Plasmin activity across GA; (B) human urokinase-type plasminogen activator (uPA) across GA; (C) human tissue-type plasminogen activator (tPA) across GA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across GA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay

    The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postmenstrual age (PMA). (A) Plasmin activity across PMA; (B) human urokinase-type plasminogen activator (uPA) across PMA; (C) human tissue-type plasminogen activator (tPA) across PMA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across PMA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Journal: Frontiers in Pediatrics

    Article Title: Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk

    doi: 10.3389/fped.2022.917179

    Figure Lengend Snippet: The levels of plasmin system components in milk from extremely preterm-(EP), very preterm-(VP), and term-delivering mothers across postmenstrual age (PMA). (A) Plasmin activity across PMA; (B) human urokinase-type plasminogen activator (uPA) across PMA; (C) human tissue-type plasminogen activator (tPA) across PMA; (D) human plasminogen activator inhibitor type 1 (PAI-1) across PMA in human milk from EP ( n = 20), VP ( n = 12), term groups ( n = 8), and combined groups (overall, n = 40). r , Spearman correlation.

    Article Snippet: The concentrations of human urokinase-type plasminogen activator (uPA), human tissue-type plasminogen activator (tPA), human plasminogen activator inhibitor type 1 (PAI-1), human PAI-1/uPA complex and PAI-1/tPA complex were determined using ELISA kits (IHUPAKT, IHTPAKT, IHPAIKT, IHPAIUPAKT-COM, and HPAITPAKT-COM, Innovative Research, Inc.) according to the protocols described by the manufacturer.

    Techniques: Activity Assay